Acute Coronary SyndromeNCT03596944
Primary Prevention With Statin and Incidence of Recurrent MI and Cardiogenic Shock in Post-ACS Patients
An observational study of Acute Coronary Syndrome and Recurrent Myocardial Infarction, run by Tarumanagara University at 1 site in Indonesia.
Trial summary
This study aims to evaluate the effect of statin for primary prevention, towards lowering the incidence of recurrent myocardial infarction, cardiogenic shock and mortality in ACS patients. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Acute Coronary Syndrome, Recurrent Myocardial Infarction, Cardiogenic Shock
- What is being tested?
- Statin
- How many people
- 145 participants
- Where
- 1 siteIndonesia
- Study dates
- 1 Aug 2017to 31 Aug 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Adult patients (≥ 18 years of age) with acute coronary syndrome which are diagnosed under International Classification of Diseases (ICD)10 coding of I24.9
Who may be able to join
- Clinical diagnosis of Acute Coronary Syndrome
- Presence of detail on statin prescription history
Who cannot join
- Unavailability of electrocardiographic findings, cardiac marker results, GRACE and TIMI score parameters
- Incomplete records of prior medical and treatment history
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Primary Prevention With Statin and Incidence of Recurrent Myocardial Infarction and Cardiogenic Shock in Post-Acute Coronary Syndrome Patients
This study aims to evaluate the effect of statin for primary prevention, towards lowering the incidence of recurrent myocardial infarction, cardiogenic shock and mortality in ACS patients.
Read the detailed description
Adult patients (≥ 18 years of age) with acute coronary syndrome which are diagnosed under ICD-10 coding of I24.9 were included in this study. The inclusion criteria are patients with primary diagnosis of I24.9 and with a complete record of prior medical and treatment history, electrocardiographic findings, cardiac marker results and outcomes. Participants were grouped into 2 groups - statin and non-statin based on prior history of statin use prior to ACS. Diagnosis of ACS was made based on clinical, electrocardiographic and cardiac marker findings found in the medical record.
Data such as age, sex, ethnic, education, prior medical and treatment history, electrocardiographic and cardiac enzyme results as well as outcomes were collected from the patients' medical records. Outcomes of interest were defined as either recurrent myocardial infarction, cardiogenic shock, mortality or combinations of them as diagnosed in the medical records. GRACE and TIMI Scores are calculated to predict in hospital and future mortality rates.
- Being tested
- Statin
- Keywords
- acute coronary syndrome, statin, mortality, GRACE score, TIMI score
- Medical subject headings
- Acute Coronary Syndrome, Myocardial Infarction, Shock, Cardiogenic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
StatinDrug
Prescribed with statins for primary prevention
| Study group | Role | What they receive |
|---|---|---|
| Statin | History of statin use for primary prevention Receives: Drug: Statin | |
| Non-Statin | No documented history of statin use prior to Acute Coronary Syndrome |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recurrent Myocardial Infarction
Clinical Diagnosis of Recurrent Myocardial Infarction reported in medical records
Measured: Through study completion, an average of 1 year
Cardiogenic Shock
Clinical Diagnosis of Cardiogenic Shock reported in medical records
Measured: Through study completion, an average of 1 year
Mortality
Patient death reported in medical records
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2018
- Study start1 Aug 2017
- Primary completion30 Jun 2018
- Study completion31 Aug 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Coronary SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 145 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tarumanagara University
- Sponsor type
- University, hospital or other
- Collaborators
- Cengkareng General Hospital
- Responsible party
- Principal investigator, Angela Felicia Sunjaya, Tarumanagara University
- Investigators
- Angela F Sunjaya, Study chair, Tarumanagara UniversityAnthony P Sunjaya, Principal investigator, Tarumanagara UniversityAndria Priyana, MD, FIHA, Principal investigator, Department of Cardiology, Faculty of Medicine, Tarumanagara University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03596944
- Sponsor's protocol ID
- APS005
- Status last verified
- Sep 2018
- First submitted
- 12 Jul 2018
- Last updated
- 12 Sep 2018
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Sep 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Primary Prevention With Statin and Incidence of Recurrent Myocardial Infarction and Cardiogenic Shock in Post-Acute Coronary Syndrome Patients
- ClinicalTrials.gov ID
- NCT03596944
- Acronym / sponsor ID
- APS005
- Keywords
- acute coronary syndrome, statin, mortality, GRACE score, TIMI score
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 145 participants (actual)
- Lead sponsor
- Tarumanagara UniversityUniversity, hospital or other
- Collaborators
- Cengkareng General Hospital
- Study start
- 1 Aug 2017 (actual)
- Primary completion
- 30 Jun 2018 (actual)
- Study completion
- 31 Aug 2018 (actual)
- First posted
- 24 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the effect of statin for primary prevention, towards lowering the incidence of recurrent myocardial infarction, cardiogenic shock and mortality in ACS patients.
Detailed description
Adult patients (≥ 18 years of age) with acute coronary syndrome which are diagnosed under ICD-10 coding of I24.9 were included in this study. The inclusion criteria are patients with primary diagnosis of I24.9 and with a complete record of prior medical and treatment history, electrocardiographic findings, cardiac marker results and outcomes. Participants were grouped into 2 groups - statin and non-statin based on prior history of statin use prior to ACS. Diagnosis of ACS was made based on clinical, electrocardiographic and cardiac marker findings found in the medical record.
Data such as age, sex, ethnic, education, prior medical and treatment history, electrocardiographic and cardiac enzyme results as well as outcomes were collected from the patients' medical records. Outcomes of interest were defined as either recurrent myocardial infarction, cardiogenic shock, mortality or combinations of them as diagnosed in the medical records. GRACE and TIMI Scores are calculated to predict in hospital and future mortality rates.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Statin | – | Drug: StatinHistory of statin use for primary prevention |
| Non-Statin | – | –No documented history of statin use prior to Acute Coronary Syndrome |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Adult patients (≥ 18 years of age) with acute coronary syndrome which are diagnosed under International Classification of Diseases (ICD)10 coding of I24.9
Key inclusion criteria (2 listed)
- Clinical diagnosis of Acute Coronary Syndrome
- Presence of detail on statin prescription history
Key exclusion criteria (2 listed)
- Unavailability of electrocardiographic findings, cardiac marker results, GRACE and TIMI score parameters
- Incomplete records of prior medical and treatment history
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| StatinPrescribed with statins for primary prevention | Drug | Statin |
Primary outcome
Recurrent Myocardial Infarction
Time frame: Through study completion, an average of 1 year
Clinical Diagnosis of Recurrent Myocardial Infarction reported in medical records
Cardiogenic Shock
Time frame: Through study completion, an average of 1 year
Clinical Diagnosis of Cardiogenic Shock reported in medical records
Mortality
Time frame: Through study completion, an average of 1 year
Patient death reported in medical records
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Sep 2018.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Coronary Syndrome
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
AI-Assisted Interpretation of Cardiac CT in the Emergency Department
Chest Pain, Acute Coronary Syndrome
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Angela F Sunjaya study chair
Tarumanagara University
Anthony P Sunjaya principal investigator
Tarumanagara University
Andria Priyana, MD, FIHA principal investigator
Department of Cardiology, Faculty of Medicine, Tarumanagara University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndrome and Recurrent Myocardial Infarction, run by Tarumanagara University at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recurrent Myocardial Infarction (time frame: Through study completion, an average of 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2018.